anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Bone marrow is soft tissue found inside the large bones of the body. Bone marrow produces red blood cells, white blood cells, and platelets that are eventually released into the blood stream. These three cell types are considered mature cells (adult cells) and they come from a progenitor cell that lives in the bone marrow. This study is designed to provide bone marrow aspirate and blood cells for research studies by basic investigators within NIA. Volunteers are screened by a health history questionnaire, a physical examination by the principal investigator, and blood tests to detect any obvious blood diseases, or bleeding or immune disorders. A bone marrow aspirate procedure is performed using a needle inserted into the hip bone to withdraw a small amount of fluid from the bone marrow for studies. NIA Researchers will use these samples for in vitro research only. In other words, these cells are never given back to a human. We will not share samples or data with researchers outside NIH.

The study population consists of healthy males and females aged 18 years and older. Study subjects are anticipated to be non-patient community volunteers. Individuals will not be excluded based on gender, race, or ethnicity. The number of subjects to be enrolled will be 2000. This will allow us to try and maintain 200 active participants in this protocol. Volunteers are screened initially and once every 2 years while on-study by a health history questionnaire and laboratory testing. Although participants may undergo a bone marrow aspirate procedure every 56 days in clinical practice, it is our plan to collect longitudinal data and obtain one sample once every other year.

We will collect bone marrow aspirate samples for distribution to NIA research investigators for their studies of the aging process in progenitor cells. We will be performing bone marrow aspirate collections of 1-5 samples every other week. We will need to maintain an active volunteer pool of approximately 200 active volunteers.
This is a single center study. A total of 36 adult volunteers will be consented for the study. Volunteers will be admitted for an overnight stay. Half will be female and half male. Twelve volunteers will have a body mass index (BMI) less than 25 kg/m2, 12 will have a BMI 25-40 kg/m2, and 12 will have a BMI greater than 40 kg/m2. Volunteers will have height and weight measured after they have consented to participate. Exactly half the volunteers in each category will received a single dose of intravenous micafungin of 100 mg, while the other half will receive 300 mg as determined by a coin flip. The volunteers will have blood drawn via an intravenous catheter just prior to the dose, and then at 1, 4, 8, 12, 16, and 24h after the drug dose. The intravenous catheter is then removed after the 24h blood draw, and the volunteer discharged from the study. Compensation will be provided to the participants for their time.
An additional group of 652 people received the trial vaccine in a 0 -, 7 -, and 21-day schedule (two first doses for a total of four doses). Blood samples were collected at 0, 7/14 and 35/42 days for antibody detection, and all subjects were systematically observed for safety.
INTRODUCTION: The electronic collection of patient data is used for a large variety of conditions. The boundaries of its use in initial diagnostics and the extent to which it can replace specialist contact, however, remain vague. Our newly developed virtual diagnostic process for common sleep disorders involves digital questionnaire administration, neurophysiological diagnostic studies, and virtual consultation with a sleep specialist. In this study, we evaluated patients' virtual diagnostic process experiences as part of a full evaluation of this process.
METHODS: Patients who completed the virtual diagnostic process participated in online semi-structured interviews based on the following criteria: age ≥ 18 years, no obvious cognitive deficits, and access to the internet. Patients who did not complete the virtual diagnostic process were contacted by telephone and given the opportunity to explain why.
RESULTS: Of the 24 patients included, 14 completed the virtual diagnostic process. Most participants understood the concept of the virtual diagnostic process, could navigate the process, and felt that the combined use of a questionnaire and virtual consultation was meaningful. Although participants could provide information as free text, the simplified closed questions, required for diagnostic classification, triggered feelings of insecurity and the inability to sufficiently describe symptoms, thereby evoking concern. All patients deemed the complementary personal contact important.
DISCUSSION: The findings demonstrate that the virtual diagnostic process is feasible and highly accepted by most patients. However, (virtual) personal (telephone or video) contact is mandatory to address patients' concerns. The virtual diagnostic process application evaluated here likely represents the outer limit of the use of electronic data collection in virtual diagnostic procedures.
Patient will undergo a RTSA as per standard technique. It uses a stemmed metal humeral component attached to the glenoid and the shallow glenoid component attached to the humerus. Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric ("high side") anterior reaming to within \< 10 degrees of neutral glenoid version. Standard instruments including a spherical burr and power reamers will be used to achieve this.
Patients with ARDs who received the vaccine at study entry (P1) (n = 590). ARD patients will be randomly assigned in a 1:1 ratio, with the use of an automated Web and telephone system, to one of two subgroups: P1, patients allocated to receive vaccine right after randomization (at D0 and D42), and P2, patients allocated to receive placebo at D0 and D42. Subsequently, blindness will be broken at D84 and P2 patients will receive vaccine doses at the D84 and D126.
The FiSK Junior study compares the effects of consuming oily fish versus poultry (control) in healthy 8-9 year-old Danish children. The children will be randomized to consume approximately 300 g/week of either oily fish or poultry for 12 weeks. Measurements and biological sampling will be performed at baseline and at the end of the intervention.

The main objective of the study is to investigate the effect on cardiovascular risk markers, primarily blood pressure and plasma triacylglycerol. Moreover, the effects on cognitive function, behaviour, emotions and physiological stress response will be assessed. In addition, change in n-3 long chain polyunsaturated fatty acid status (compliance), anthropometry, body composition, vitamin D status, inflammatory markers, growth markers, physical activity and diet will be measured. Outcomes will be analysed with focus on potential gender- and genotype-specific effects.
The present invention discloses a method of preparing hud type nanometer/micron fibers or capsules for use of slow releasing medication, which adopts a double-layer spinning head comprising an inner layer and an outer layer. Oil-soluble medicines, water-soluble medicines or the mixture thereof and the solution of two identical or different polymers respectively pass through the inner layer and the outer layer of the double-layer to form nanometer/micron fibers or capsules under high-pressure electrostatic action. The oil-soluble medicines, water-soluble medicines or the mixture thereof is directed embedded into the outer layers and the inner layers or the two layers of the nanometer/micron fibers or capsules. The present invention prepares required equipment and has the advantages of simple technological process and little energy consumption. All medicines which comprise hydrophobic and water-soluble medicines can be loaded into the nanometer/micron fibers or capsules in high embedding rates. Because of mild preparation conditions, the method is suitable for biologically active materials with changeability and deactivation, including polypeptide protein, growth factors, DNA, etc. The release speeds of the medicines can be regulated and controlled. The obtained nanometer/micron fibers can be directly used as tissue engineering brackets and are used for cell cultivation.
Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
PROBLEM TO BE SOLVED: To btain a pasty medicinal composition containing a water-insoluble or sparingly water-soluble medicinal agent, and esp. suitable for rectal administration as an anti-inflammatory/analgesic agent. SOLUTION: This medicinal composition contain 1-10wt.% of a water- insoluble or sparingly water-soluble medicinal agent (e.g. diclofenac, indomethacin), 0.5-20wt.% of a starch, 1-50wt.% of a sugar alcohol, and water. It is preferable that this composition is prepared by formulating the above ingredients with, optionally, commonly used stabilizer, pH adjustor, thickening agent, viscolizer, water-holding agent, antiseptic, etc., followed by packing a coelomic syringe with the resultant formulation for injecting it into the nasal cavity, vagina, ear cavity etc., (esp. pref. for the injection into the rectum). This medicinal composition, which is excellent in preservability and hygienic and safe when used and can be surely injected into the body cavity, is applicable to treating low back pain, osteoarthropathy, chronic arthrorheumatism, neuropathy, pharynx/larynx inflammation, etc.
Participants received indacaterol 150 μg delivered via a single-dose dry-powder inhaler (SDDPI) plus placebo to tiotropium delivered via the manufacturer's proprietary inhalation device (HandiHaler®) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
Deregulation of small non-coding RNAs (sncRNAs) has been associated with the onset of metastasis. We evaluated the expression of sncRNAs in patients with early-stage breast cancer, performing RNA sequencing in 60 patients for whom tumor and sentinel lymph node (SLN) samples were available, and conducting differential expression, gene ontology, enrichment and survival analyses. Sequencing annotation classified most of the sncRNAs into small nucleolar RNA (snoRNAs, 70%) and small nuclear RNA (snRNA, 13%). Our results showed no significant differences in sncRNA expression between tumor or SLNs obtained from the same patient. Differential expression analysis showed down-regulation (n = 21) sncRNAs and up-regulation (n = 2) sncRNAs in patients with locoregional metastasis. The expression of SNHG5, SNORD90, SCARNA2 and SNORD78 differentiated luminal A from luminal B tumors, whereas SNORD124 up-regulation was associated with luminal B HER2+ tumors. Discriminating analysis and receiver-operating curve analysis revealed a signature of six snoRNAs (SNORD93, SNORA16A, SNORD113-6, SNORA7A, SNORA57 and SNORA18A) that distinguished patients with locoregional metastasis and predicted patient outcome. Gene ontology and Reactome pathway analysis showed an enrichment of biological processes associated with translation initiation, protein targeting to specific cell locations, and positive regulation of Wnt and NOTCH signaling pathways, commonly involved in the promotion of metastases. Our results point to the potential of several sncRNAs as surrogate markers of lymph node metastases and patient outcome in early-stage breast cancer patients. Further preclinical and clinical studies are required to understand the biological significance of the most significant sncRNAs and to validate our results in a larger cohort of patients.
Understanding the sexual dimorphism in diseases is essential to investigate the pathogenesis of some chronic diseases (e.g., autoimmune diseases, etc). The gut microbiota has been found to show a notable impact on the pathology of several chronic diseases in recent years. Intriguingly, the composition of the gut microbiota varies between sexes. Here, we reviewed 'facts and fiction' regarding sexual dimorphism in chronic diseases and sexual dimorphism in the gut microbiota respectively. The association and causative relationship between them aiming to elucidate the pathological mechanisms of sexual dimorphism in chronic diseases were further explored. The development of gender-special food products based on the sexual dimorphism in the gut microbiota were recommended, which would be beneficial to facilitating the personalized treatment.
FIELD: medicine, narcology. SUBSTANCE: method involves the use of furadonin at doses 0.15-0.2 g, 3-4 times per a day for 10-20 days. After 5-7 days of treatment alcoholic tests were carried out by fractional alcoholic drinks beginning from 15-30 ml vodka up to 4 doses during one test. Also, furadonin is used for alcoholism relapses prophylaxis at dose 0.1-0.2 g, 2-3 times per a day for 10-20 days and more. EFFECT: enhanced effectiveness of treatment, broadened spectrum of drugs. 2 cl
Participants with genetic variation in their VDR, GC and CYP2R1 genes that moderately increase their risk of vitamin D deficiency. Participants will be given 10µg vitamin D supplements for 90 days. This group will be compared against the low-risk control group to determine the effect of genetic variations on vitamin D status.
BACKGROUND: Recent studies have linked recurrent pregnancy loss (RPL) to abnormalities in the sperm genome, specifically microdeletions in the azoospermia factor (AZF) region. This study investigated the potential association between Y chromosome microdeletions in the AZF region and RPL in Iranian couples.
METHODS: The research presents a case-control study of 240 men: 120 whose partners experienced recurrent miscarriage, and 120 who had successful pregnancies without history of miscarriage. The study used semen parameters, hormone analyses, and microdeletion analysis via multiplex PCR and the YChromStrip kit. Thus, the sequence-tagged site (STS) markers of AZFa (sY84, sY86), AZFb (sY127, sY134), and AZFc (sY254, sY255) regions were examined.
RESULTS: The variations in semen parameters and sex hormone levels between cases and controls are suggest impaired testicular function in men whose partners had recurrent miscarriages (p < 0.05). Furthermore, the study revealed a negative correlation between sperm count and follicle-stimulating hormone (FSH) level, and a positive one between sperm motility and testosterone concentration. There were no microdeletions in the control group, while the RPL group showed 20 deletions in AZFb (sY134) (16.66%) and 10 deletions each in AZFb (sY127) (8.33%) and AZFc (sY254) (8.33%).
CONCLUSION: Microdeletions in sY134 (AZFb) were significantly associated with RPL in Iranian men (p = 0.03). AZF microdeletion screening in couples with RPL can provide valuable information for ethnical genetic counseling and management of recurrent miscarriage. Further studies on larger populations or across various ethnic groups, conclusions and the inclusion of other factors like epigenetic changes explain the role of AZF microdeletions in RPL.
The invention discloses a visual sense feeling relaxation apparatus. The relaxation apparatus comprises medicament bags. A Chinese medicament mixture is placed in the medicament bags, wherein the Chinese medicament mixture comprises the following components in part by weight: 50 to 120 parts of rehmanniae vaporata, 10 to 30 parts of cornus, 20 to 50 parts of dioscoreae, 15 to 50 parts of tortoise plastron, 10 to 30 parts of tribulus terrestris, and 1 to 4 parts of velvet deerhorn. The Chinese medicament mixture can also comprises the following components in part by weight: 10 to 30 parts of poria and 10 to 20 parts of alismatis. The Chinese medicament mixture can also comprises the following components in part by weight: 10 to 20 parts of root-bark of tree peony, 20 to 40 parts of chrysanthemum flower, and 10 to 30 parts of abalone shell. The medicament mixture is absorbed into spinal nerves through eyeball nerve endings and then is delivered to all parts of a body to play a role in dissipating fatigue and relaxing the feeling at peripheral nerves. The visual sense feeling relaxation apparatus has good effects of treating all the following various chronic diseases such as headache, dizziness, insomnia, dreaminess, cerebral angiospasm, fast cardiac rate, liver and kidney diseases, complications of diabetes, and the like.
PCT No. PCT/GB96/00979 Sec. 371 Date Oct. 22, 1997 Sec. 102(e) Date Oct. 22, 1997 PCT Filed Apr. 24, 1996 PCT Pub. No. WO96/34101 PCT Pub. Date Oct. 31, 1996Mouse and human utrophin gene promoters are provided. The promoters or fragments and derivatives may be used to control transcription of heterologous sequences, including coding sequences of reporter genes. Expression systems such as host cells containing nucleic acid constructs which comprise a promoter as provided operably linked to a heterologous sequence may be used to screen substances for ability to modulate activity of the utrophin promoter. Substances with such ability may be manufactured and/or used in the preparation of compositions such as medicaments. Up-regulation of utrophin expression may compensate for dystrophin loss in muscular dystrophy patients.
Patients in the intervention arm will be given a FitBit device and will be encouraged to wear it as often as possible. Using FitBit built-in tracking technologies such as PurePulse and SmartTrack54, patient's daily activities such as number of steps taken, sedentary time, heart rate, sleep time and exercise will be captured and synced to the adaptive intervention platform as developed in Phase 2 for real-time tracking.
The present invention relates to antigen-binding polypeptides, particularly antibody fragments, and especially single-chain antibodies, which specifically bind to bovine coronavirus spike glycoprotein (S2). The polypeptides neutralize the cytopathic changes of cells by bovine coronavirus and/or have a protective and/or curative effect on infection of mammals, especially calves and cattle, by viruses expressing spike glycoprotein (S2). The polypeptides may be expressed in a prokaryotic or eukaryotic host cell, preferably a bacterial, yeast or plant cell. Also provided are transgenic plants or parts thereof and microorganisms expressing the polynucleotides of the present invention. The plants or plant parts expressing the polypeptides may be used as fodder for mammals and especially calves and cattle. Furthermore, the invention relates to polynucleotides encoding said spike glycoprotein (S2)-binding polypeptides, vectors comprising these polynucleotides, host cells comprising these polynucleotides or vectors, compositions comprising said spike glycoprotein (S2)-binding polypeptides, and methods of producing said polypeptides.
With support from the American Cancer Society, Dr. Park designed a 5-session health insurance navigation treatment program, Health Insurance Navigation Tools (HINT), that is currently being delivered remotely, as a collaboration with the Childhood Cancer Survivor Study. Given the current insurance landscape and the additional insurance burden that adult colorectal cancer survivors face, the present study seeks to conduct a pilot trial with the existing health insurance intervention and adult colorectal cancer survivors seen at MGH Cancer Centers to improve health insurance literacy and decrease financial burden related to medical costs. The present study seeks to develop and pilot a health insurance navigation program with adult colorectal cancer survivors recruited from MGH. Patients diagnosed with colorectal cancer have a higher risk of experiencing financial burden related to health care costs when compared to patients diagnosed with other types of cancer. While many cancer survivors report experiencing financial burden, financial burden is particularly acute among survivors of colorectal cancer. Outcomes of financial burden among colorectal cancer survivors include lower health related quality of life, employment concerns, and delay or lack of engagement in needed surveillance and follow-up care.

Understanding and navigating insurance benefits in the current landscape is crucial for colorectal cancer survivors to obtain and utilize the health care that they need. With this in mind, the study investigators propose to develop and pilot an insurance navigation intervention to examine its feasibility and acceptability among colorectal cancer survivors receiving care at the MGH.
FIELD: agriculture. ^ SUBSTANCE: this invention relates to food and feed supplements and application thereof. Both food and feed supplements include as the main component at least one carboxylic acid and/or oxysalt, iron component and vitamins B6, B9 and B12 in amounts corresponding at least to those that can be theoretically consumed during metabolism of present COOH-groups of carboxylic acid. These supplements can also include desiccant and antioxidant. They will have pH from 2.0 to 6.0 as dissolved in water. Both supplements are characterised with amount of vitamins B6, B9 and B12 ranging from 0.5 to 30 mg, 0.1-10 mg and 1-1500 mkg/gram of dry weight of pure carboxylic acids in supplement, correspondingly. As nutrition for people the supplement is used by means of introducing from 0.1 to 4.4 mg of daily intake of dry weight of pure carboxylic acids in supplement per a kilogram of body weight. This supplement can be applied as feed for animals in amounts from 0.5 to 15 grams of dry supplement per kilo of dry feed during physical activities or competition, as well as in feed for horses by mixing from 1 to 15 grams of dry weight of pure carboxylic acids in supplement per 100 kg of horse weight with normal horse feed. ^ EFFECT: supplements according to the invention enable to improve level of health and activity, particularly in stress state and under conditions when high achievements are required, for example during training and competitions. ^ 13 cl, 5 tbl, 6 ex